Puma Biotechnology, Inc.

NasdaqGS:PBYI Stock Report

Market Cap: US$174.3m

Puma Biotechnology Future Growth

Future criteria checks 0/6

Puma Biotechnology's revenue and earnings are forecast to decline at 4.1% and 47.6% per annum respectively while EPS is expected to decline by 45.9% per annum.

Key information

-47.6%

Earnings growth rate

-45.9%

EPS growth rate

Biotechs earnings growth26.7%
Revenue growth rate-4.1%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Dec 2024

Recent future growth updates

Recent updates

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Dec 16

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Earnings and Revenue Growth Forecasts

NasdaqGS:PBYI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027200-1044N/A1
12/31/20262272050602
12/31/20252212058462
12/31/20242241551392
9/30/2024244233434N/A
6/30/202421993333N/A
3/31/2024227153536N/A
12/31/2023236221427N/A
9/30/20232294524N/A
6/30/2023230-21131N/A
3/31/20232355-614N/A
12/31/20222280-23-16N/A
9/30/202221810-29-29N/A
6/30/2022207-34-36-36N/A
3/31/2022201-49-22-22N/A
12/31/2021253-292121N/A
9/30/2021250-482020N/A
6/30/2021255-351212N/A
3/31/2021272-271828N/A
12/31/2020225-60-91N/A
9/30/2020235-56-28N/A
6/30/2020241-42-11-1N/A
3/31/2020224-822727N/A
12/31/2019272-762222N/A
9/30/2019280-952828N/A
6/30/2019287-922828N/A
3/31/2019284-99-35-34N/A
12/31/2018251-114-25-24N/A
9/30/2018202-147-117-67N/A
6/30/2018145-210N/A-114N/A
3/31/201894-243N/A-143N/A
12/31/201728-292N/A-172N/A
9/30/20176-301N/A-178N/A
6/30/2017N/A-289N/A-158N/A
3/31/2017N/A-278N/A-143N/A
12/31/2016N/A-276N/A-142N/A
9/30/2016N/A-265N/A-134N/A
6/30/2016N/A-260N/A-136N/A
3/31/2016N/A-258N/A-139N/A
12/31/2015N/A-239N/A-154N/A
9/30/2015N/A-225N/A-140N/A
6/30/2015N/A-200N/A-127N/A
3/31/2015N/A-175N/A-110N/A
12/31/2014N/A-142N/A-77N/A
9/30/2014N/A-110N/A-72N/A
6/30/2014N/A-89N/A-60N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PBYI's earnings are forecast to decline over the next 3 years (-47.6% per year).

Earnings vs Market: PBYI's earnings are forecast to decline over the next 3 years (-47.6% per year).

High Growth Earnings: PBYI's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PBYI's revenue is expected to decline over the next 3 years (-4.1% per year).

High Growth Revenue: PBYI's revenue is forecast to decline over the next 3 years (-4.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PBYI's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 16:37
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Puma Biotechnology, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Geoffrey MeachamBofA Global Research
Alethia YoungCantor Fitzgerald & Co.